, a Bethesda, Md.-based developer of drugs based on prostones, a class of compunds, today set the terms of its IPO of 3.75 million Class A common shares at an estimated price of $14 to $16 per share. The company plans to list on the Nasdaq under the symbol SCMP. Cowen & Co., CIBC World Markets and Leerink Swann & Co. are serving as underwriters. The company raised $25 million in venture funding from such firm as Diamond Capital, Fujisawa Research Institute of America, Intel Capital and Mizuho Capital Co. www.sucampo.com
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.